logo

Comparison of the efficacy and safety of tolterodine 2 mg and 4 mg combined with an α-blocker in men with lower urinary tract symptoms (LUTS) and overactive bladder: a randomized c[...]
Every Week the Editor-in-Chief selects an Article of the Week from the current issue of BJUI. The abstract is reproduced below and you can click on the button to read the full arti[...]
Russo et al. [1] have identified LUTS as an independent risk factor for cardiovascular disease (CVD). The more severe the LUTS the more the CVD risk increased. LUTS in men is cause[...]
Increase of Framingham cardiovascular disease risk score is associated with severity of lower urinary tract symptoms Giorgio I. Russo, Tommaso Castelli, Salvatore Privitera, Eugeni[...]
“It is my ambition to say in ten sentences what others say in a whole book.” – Friedrich Nietzsche The EAU guidelines on lower urinary tract symptoms have been published rece[...]
Every Week the Editor-in-Chief selects an Article of the Week from the current issue of BJUI. The abstract is reproduced below and you can click on the button to read the full arti[...]
In recent decades we have had access to an increasing body of evidence evoking a strong relationship between metabolic syndrome and the development of LUTS/BPH. This relationship s[...]
  Central obesity is predictive of persistent storage LUTS after surgery for Benign Prostatic Enlargement: results of a multicenter prospective study Mauro Gacci, Arcangelo Se[...]
Several new surgical technologies have been assessed during the last decades in order to improve the management of LUTS (Lower Urinary Tract Symptoms): HoLEP (Holmium laser enuclea[...]
Every Week the Editor-in-Chief selects an Article of the Week from the current issue of BJUI. The abstract is reproduced below and you can click on the button to read the full arti[...]